IBL-202
Aggressive B-cell malignancies, T-cell lymphoma (e.g., PTCL)
Pre-clinicalActive
Key Facts
Indication
Aggressive B-cell malignancies, T-cell lymphoma (e.g., PTCL)
Phase
Pre-clinical
Status
Active
Company
About Inflection Biosciences
Inflection Biosciences is a private, pre-revenue biotech developing novel dual PIM/PI3K kinase inhibitors for oncology and inflammatory diseases. Its lead asset, IBL-202, is in pre-clinical development for aggressive B-cell malignancies and T-cell lymphoma, while AUM302 (IBL-302) is partnered with AUM Biosciences. The company leverages a network of academic collaborations, including a foundational license from the Spanish National Cancer Research Centre (CNIO), and has secured non-dilutive funding from the EU's Horizon 2020 program.
View full company profile